AstraZeneca CEO says lung cancer drug trial data 'very encouraging'
Send a link to a friend
[July 29, 2023]
By Maggie Fick and Josephine Mason
LONDON (Reuters) -AstraZeneca Chief Executive Pascal Soriot said on
Friday the company is "very encouraged" by interim data from a key lung
cancer drug trial, but he did not explain why the company had not
declared results as "clinically meaningful".
The drugmaker's shares fell by as much as 8% earlier this month after
the company released interim data from the late-stage clinical trial
called TROPION-Lung01 testing an experimental precision drug called
datopotamab deruxtecan.
At the time, investors were disappointed the company did not say the
data was "clinically meaningful", a potential suggestion that the
benefits may not be as pronounced as hoped.
Speaking to media on Friday after the company released
better-than-expected quarterly results, Soriot said people would
understand when full results are released why the company did not use
that description, but he did not comment further.
"We are very encouraged because we're seeing the totality of the data,"
he said, adding that the company had described them as "statistically
positive".
![](http://archives.lincolndailynews.com/2023/Jul/29/images/ads/current/charrons_bch_2022.png)
[to top of second column]
|
![](../images/072923PIX/health31.jpg)
The company logo for pharmaceutical
company AstraZeneca is displayed on a screen on the floor at the New
York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File
Photo/File Photo
![](http://archives.lincolndailynews.com/2019/Sep/05/images/ads/current/stclara_lda_SPONSOR_090519.png) The company said on Friday it will
continue with its plan to file data from the trial with the U.S.
Food and Drug Administration (FDA), soothing some investor concerns.
In a briefing with analysts, Susan Galbraith, executive vice
president of oncology R&D, said the FDA response to the data so far
had been "encouraging".
Executives on the briefing would not say when final data will be
released or at which medical conference, or when the company will
file for approval for the drug with the U.S. drug regulator.
(Reporting by Maggie Fick and Josephine Mason; editing by David
Evans and Susan Fenton)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |